Kim et al. showed that the ADC difference value derived from whole-lesion histogram analysis can be used to assess the recurrence risk in invasive BC patients with positive estrogen receptor (ER), negative HER-2, and negative node disease [14]. The gene discussed is ERBB2; the disease is breast cancer.